文献速递药物不良反应与药物警戒抗栓抗凝管理

免疫检查点抑制剂与静脉血栓栓塞:WHO药物警戒数据库分析

Immune Checkpoint Inhibitors and Venous Thromboembolism: An Analysis of the WHO Pharmacovigilance Database.
PubMed 文献 · Clin Pharmacol Ther · 2022-05-02

纳入2008年1月1日至2021年5月31日期间癌症患者涉及至少一种抗癌药物作为可疑或相互作用药物的报告。结果显示ICIs未增加VTEs报告风险(粗ROR 0.63,95%CI 0.60-0.67;调整ROR 0.70,95%CI 0.65-0.74)。

要点

  • ICIs与静脉血栓栓塞事件报告风险无显著升高,粗ROR 0.63(95%CI 0.60-0.67)
  • 调整年龄、性别及合并用药后,调整ROR 0.70(95%CI 0.65-0.74)
  • 各ICIs类别均未发现不成比例报告信号

核心结论

  • 与其他抗癌药物相比,ICIs未增加静脉血栓栓塞事件的报告风险。

研究设计与样本

  • 纳入2008年1月1日至2021年5月31日期间癌症患者涉及至少一种抗癌药物作为可疑或相互作用药物的报告。

主要发现

  • 共有1196例ICIs治疗后发生VTEs的患者,中位年龄65岁,57.6%为男性。
  • 抗PD-1药物是最常报告的药物类别(62.5%)。
  • ICIs与其他抗癌药物比较,粗ROR 0.63(95%CI 0.60-0.67),调整ROR 0.70(95%CI 0.65-0.74)。
  • 未发现各ICIs类别存在不成比例报告信号。

关键数值与推荐

  • 粗报告比值比(ROR)0.63(95%CI 0.60-0.67),以其他抗癌药物为对照。
  • 调整年龄、性别及与VTEs风险相关的其他药物(不包括抗癌药物)后,调整ROR 0.70(95%CI 0.65-0.74)。

临床怎么用

  • 临床中不应仅因使用ICIs而常规增加对VTEs的额外监测,但需结合患者个体血栓风险综合评估。

局限性

  • 药物警戒研究存在固有局限性,如报告偏倚、混杂因素控制不充分等。
  • 需要包含合适对照组的前瞻性研究来评估ICIs治疗患者的VTEs风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Data on venous thromboembolic events (VTEs) in patients receiving immune checkpoint inhibitors (ICIs) are scarce and conflicting. This study investigated the risk of reporting VTEs associated with ICIs in comparison with all other anticancer drugs. The World Health Organization pharmacovigilance database (VigiBase), comprising >30 million individual case safety reports, was queried. All reports on patients with cancer, involving at least one anticancer drug as a suspect or interacting drug and registered from January 1, 2008, to May 31, 2021, were included. The association between ICIs and the risk of reporting VTEs was estimated using the reporting odds ratio (ROR) as a measure of disproportionality with all other anticancer drugs as comparators. RORs were estimated as crude and adjusted RORs for age, sex, and other medications (excluding anticancer drugs) associated with risk of VTEs. Among 1,196 patients experiencing VTEs after ICI treatment, the median age was 65 years and 57.6% were men. Anti-PD-1 agents (62.5%) were the most frequently reported. ICIs were not associated with higher reporting of VTEs when compared with other anticancer drugs (crude ROR 0.63, 95% confidence interval (CI) 0.60 to 0.67 and adjusted ROR 0.70, 95% CI 0.65-0.74). No signal of disproportionate reporting was found when considering each class of ICIs. In conclusion, ICIs were not associated with higher reporting of VTEs, in comparison with all other anticancer drugs in a large-scale pharmacovigilance database. Owing to the limitations inherent to pharmacovigilance studies, prospective studies, including an adequate comparison group, are needed to assess the risk of VTEs in ICI-treated patients.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Allouchery M, Beuvon C, Pérault-Pochat MC, et al. Immune Checkpoint Inhibitors and Venous Thromboembolism: An Analysis of the WHO Pharmacovigilance Database. Clin Pharmacol Ther. 2022. PMID: 35426120. doi:10.1002/cpt.2615

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。